Indian Perspective of Atherogenic Dyslipidemia and Role of Saroglitazar


Dr Shashank Joshi, Mumbai    31 January 2018

  1. diabetes treated with statins.
  2. Therapy with statin and TG-lowering combination may be considered for men with both TG level ≥204 mg/dl and HDL-C level ≤34 mg/dl.
  3. For high TG, treatment should be initiated: For CV risk reduction - when TG >200 mg/dL; for pancreatitis risk reduction - when TG >500 mg/dL.
  4. Saroglitazar is the first approved dual PPAR-a/g agonist. It is approved for the treatment of diabetic dyslipidemia and hypertriglyceridemia in T2DM uncontrolled with statin therapy. 
  5. Saroglitazar has 11 years of research data and 4 years of post-marketing data.
  6. Saroglitazar should be used in type 2 diabetes patients with uncontrolled TG >200 mg/dl.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.